Artivion (AORT) Scheduled to Announce Quarterly Earnings on Monday

Artivion (NYSE:AORT) is scheduled to release its earnings data after the market closes on Monday, May 6th. Analysts expect Artivion to post earnings of $0.02 per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, February 15th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.24. The company had revenue of $93.67 million during the quarter, compared to the consensus estimate of $89.75 million. Artivion had a negative net margin of 8.67% and a positive return on equity of 3.02%. On average, analysts expect Artivion to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Artivion Price Performance

Shares of NYSE AORT opened at $20.93 on Friday. The stock has a market capitalization of $862.32 million, a PE ratio of -27.91 and a beta of 1.66. Artivion has a fifty-two week low of $12.16 and a fifty-two week high of $21.90. The company has a debt-to-equity ratio of 1.10, a current ratio of 4.85 and a quick ratio of 3.43. The business has a fifty day moving average price of $20.38 and a two-hundred day moving average price of $17.94.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on AORT shares. Needham & Company LLC reiterated a “buy” rating and issued a $25.00 target price on shares of Artivion in a report on Monday, April 8th. Stifel Nicolaus increased their price objective on shares of Artivion from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, February 16th.

Insiders Place Their Bets

In other Artivion news, CEO James P. Mackin sold 13,996 shares of the firm’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $18.72, for a total value of $262,005.12. Following the completion of the transaction, the chief executive officer now directly owns 705,562 shares of the company’s stock, valued at approximately $13,208,120.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO James P. Mackin sold 13,996 shares of the firm’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $18.72, for a total transaction of $262,005.12. Following the sale, the chief executive officer now owns 705,562 shares in the company, valued at approximately $13,208,120.64. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Jean F. Holloway sold 2,380 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $18.72, for a total value of $44,553.60. Following the sale, the senior vice president now owns 169,669 shares in the company, valued at approximately $3,176,203.68. The disclosure for this sale can be found here. Insiders sold a total of 149,952 shares of company stock worth $2,891,627 in the last quarter. 8.10% of the stock is owned by company insiders.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.